Aarti Drugs Ltd (AARTIDRUGS)
₹404.50
Mkt cap
₹3,402 Cr
P/E ratio
17.40
P/B
2.38
Div yield
0.54%
ROE
13.40%
ROCE
11.90%
EPS (TTM)
₹23.25
Book value
₹170
52W range
320–545
Sector
Healthcare
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1] It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−25.79% from high₹405
₹320+26.51% from low₹545
Current
₹404.50
Prev close
₹408.00
Day
−0.86%
Price performance
1D
−0.86%
1W
−3.23%
1M
+8.53%
3M
+10.31%
6M
+7.85%
1Y
−21.88%
YTD
−1.57%
Financials
FRevenue, profit & margin
P/E ratio
17.4×
AARTIDRUGS is 48% below the sector median of 33.3×
AARTIDRUGS17.4×
Sector median33.3×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 742 | 661 | 642 | 606 | 620 | 555 | 598 | 557 | 677 | 591 | 653 | 602 | 720 | |
| Expenses | 649 | 577 | 565 | 536 | 534 | 490 | 531 | 495 | 583 | 516 | 569 | 547 | 624 | |
| Operating Profit | 94 | 84 | 76 | 70 | 86 | 65 | 67 | 62 | 93 | 74 | 84 | 55 | 96 | |
| OPM % | 13% | 13% | 12% | 12% | 14% | 12% | 11% | 11% | 14% | 13% | 13% | 9% | 13% | |
| Other Income | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 12 | 2 | 0 | 0 | 1 | 1 | |
| Interest | 9 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 8 | |
| Depreciation | 12 | 13 | 13 | 13 | 14 | 13 | 14 | 14 | 15 | 15 | 16 | 18 | 18 | |
| Profit before tax | 73 | 64 | 56 | 52 | 64 | 44 | 46 | 51 | 71 | 51 | 60 | 29 | 70 | |
| Tax % | 23% | 24% | 30% | 29% | 26% | 24% | 24% | 27% | 12% | -6% | 25% | -40% | 21% | |
| Net Profit | 56 | 48 | 40 | 37 | 47 | 33 | 35 | 37 | 63 | 54 | 45 | 41 | 55 | |
| EPS in Rs | 6.06 | 5.17 | 4.31 | 3.99 | 5.15 | 3.62 | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
31 Jul '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202655.03%Promoter
Promoters55.03%
FIIs1.57%0.58
DIIs10.22%0.10
Public33.19%0.48
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,862.80 | 35.82 | 4,46,948 | 0.86% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹6,713.50 | 67.94 | 1,78,222 | 0.45% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹4,516.20 | 69.74 | 1,52,849 | 0.84% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,440.10 | 30.56 | 1,16,338 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Dr Reddy's Labs | ₹1,350.50 | 26.86 | 1,12,723 | 0.59% | 221 | −86.14% | 7,546 | −11.51% | 13.64% |
| Zydus Lifesci. | ₹1,101.40 | 20.43 | 1,10,827 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.15% |
| Lupin | ₹2,343.50 | 18.59 | 1,07,152 | 0.51% | 1,469 | +101.49% | 7,475 | +31.89% | 30.32% |
| Aarti Drugs | ₹372.70 | 17.45 | 3,402 | 0.54% | 55 | −12.20% | 720 | +6.43% | 11.90% |
| Median: 157 Co. | ₹408.30 | 33.25 | 1,798 | 0.09% | 12 | +22.34% | 177 | +16.22% | 15.14% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011nse
Concall transcripts62
Credit ratings6
Announcements5
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1d - Promoter group holding fell to 54.43% after market sales and purchases, June 2024-June 2026.Closure of Trading Window 2dAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Jun - Aarti Drugs scheduled a group investor meeting on 23 June 2026 in Tarapur.Transfer Of Equity Shares Of The Company To IEPF 16 Jun - Published notice for transfer of equity shares to IEPF account on June 16, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 Jun - Aarti Drugs schedules a virtual investor meeting on 10 June 2026 with Choice Institutional Equities.